Table 1.
The demographics and clinical features of hepatocellular carcinoma patients in model cohort and validation cohort
| Model cohort | Validation cohort | P value | |
|---|---|---|---|
| Patients (n) | 348 | 203 | |
| Death [n (%)] | 130 (37.4) | 81 (39.9) | 0.553 |
| Survival time (month) | 20.5 (11.9, 37.7) | 51.3 (16.2, 57.3) | < 0.001 |
| Age (year) | 59.5 ± 13.4 | 51.1 ± 10.6 | < 0.001 |
| Male [n (%)] | 236 (67.8) | 174 (85.7) | < 0.001 |
| Grade1 [n (%)] | 53 (15.2) | NA | |
| Grade2 [n (%)] | 163 (46.8) | NA | |
| Grade3 [n (%)] | 115 (33.0) | NA | |
| Grade4 [n (%)] | 12 (3.4) | NA | |
| AJCC PT1 [n (%)] | 171 (49.1) | NA | |
| AJCC PT2 [n (%)] | 87 (25.0) | NA | |
| AJCC PT3 [n (%)] | 74 (21.3) | NA | |
| AJCC PT4 [n (%)] | 14 (4.0) | NA | |
| AJCC PN0 [n (%)] | 244 (70.1) | NA | |
| AJCC PN1 [n (%)] | 3 (0.9) | NA | |
| AJCC PN2 [n (%)] | 100 (28.7) | NA | |
| AJCC PM0 [n (%)] | 248 (71.3) | NA | |
| AJCC PM1 [n (%)] | 100 (28.7) | NA | |
| AJCC stage1 [n (%)] | 164 (47.1) | 83 (40.9) | 0.033 |
| AJCC stage2 [n (%)] | 79 (22.7) | 71 (35.0) | |
| AJCC stage3 [n (%)] | 80 (23.0) | 48 (23.6) | |
| AJCC stage4 [n (%)] | 4 (1.1) | 0 | |
| Child–pugh1 [n (%)] | 210 (60.3) | NA | |
| Child pugh2 [n (%)] | 20 (5.7) | NA | |
| Child pugh3 [n (%)] | 1 (0.3) | NA | |
| Radiation treatment [n (%)] | 4 (1.1) | NA | |
| Pharmaceutical [n (%)] | 15 (4.3) | NA | |
| Ablation embolization [n (%)] | 13 (3.7) | NA | |
| Family history [n (%)] | 106 (30.5) | NA |
The survival time was expressed as median (first quantile, third quantile). Continuous variables were compared by t-test or Mann–Whitney U test as appropriate. Categorical variables were compared by Chi-squared test or Fisher’s exact test as appropriate